Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. (Q42817318)

7 November 2017

Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. (English)

1 reference

7 November 2017

1 reference

Iskandar Idris

1

1 reference

7 November 2017

Divina Patiag

series ordinal

2

1 reference

7 November 2017

Samuel Gray

series ordinal

3

1 reference

7 November 2017

Richard Donnelly

series ordinal

4

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

7 November 2017

Biochemical Pharmacology

1 reference

7 November 2017

63

1 reference

7 November 2017

5

1 reference

7 November 2017

993-996

1 reference

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

7 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Possible interactions between angiotensin II and insulin: effects on glucose and lipid metabolism in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900924-8

10.1016/S0006-2952(01)00924-8

7 January 2021

Identifiers

DOI

1 reference

7 November 2017

1 reference